Aduro Expands Collaboration with Johnson & Johnson Innovation and Janssen for Lung Cancer Immunotherapies
Aduro公司擴(kuò)大與強(qiáng)生創(chuàng)投公司和詹森公司在肺癌免疫療法上的合作，
Aduro BioTech has entered into its second agreement with Janssen Biotech, Inc., part of the Janssen Pharmaceutical Companies of Johnson & Johnson, granting an exclusive, worldwide license to certain product candidates engineered for the treatment of lung cancer and certain other cancers based on its novel LADD immunotherapy platform. Under the agreement, facilitated by the Johnson & Johnson Innovation center in California, Aduro will receive a $30 million up-front payment and is eligible to receive significant development, regulatory and commercialization milestone payments up to a potential total of $817 million. In addition, Aduro is eligible to receive high single-digit to double-digit tiered royalties on worldwide net sales upon successful launch and commercialization.
Audro生物科技公司與詹森強(qiáng)生公司的子公司，詹森生物科技公司訂立了第二份合作協(xié)議，授予后者排他性的、世界范圍內(nèi)的許可，基于其創(chuàng)新的LADD免疫治療平臺(tái)，來(lái)生產(chǎn)設(shè)計(jì)用來(lái)治療肺癌和其他癌癥的候選產(chǎn)品。根據(jù)協(xié)議，在位于加利福尼亞州的強(qiáng)生創(chuàng)新中心的協(xié)助下，Aduro公司將獲得3000萬(wàn)美元的預(yù)先付款，并且能夠獲得數(shù)額巨大的研發(fā)、調(diào)整和商業(yè)化階段的付款，總額預(yù)計(jì)可達(dá)到8.17億美元。另外，Aduro有資格在藥品成功發(fā)行和商業(yè)化或，獲得全世界凈銷售額一位數(shù)或兩位數(shù)的封層辦稅提成。
Under the agreement, Janssen will have exclusive rights to develop and commercialize LADD product candidates in lung cancer and will assume responsibility for all research, development, manufacturing, regulatory and commercialization activities for the licensed products. Aduro may provide assistance in any of these areas upon request and will receive additional fees for these support activities.
根據(jù)該協(xié)議，詹森公司將擁有排他性的權(quán)利來(lái)研發(fā)和商業(yè)化治療肺癌的LADD候選產(chǎn)品，并為授權(quán)產(chǎn)品所有的研究、發(fā)展、生產(chǎn)、標(biāo)準(zhǔn)和商業(yè)化承擔(dān)責(zé)任。Aduro公司可應(yīng)請(qǐng)求在所有這些方面提供支持，并因這些幫助活動(dòng)而獲得額外報(bào)酬。
"Since our initial agreement with Janssen in May of this year for new immunotherapies for prostate cancer, they have been terrific partners and we've established a strong collaboration focused on advancing our technologies forward in their licensed indications," said Stephen T. Isaacs, chairman, president and chief executive officer of Aduro. "We believe our LADD technology also offers tremendous promise as a potential treatment for lung cancer and we are pleased to expand our relationship with Janssen, a company with significant experience and resources focused in both lung and prostate cancer. Separately, Aduro continues to make progress with our broad array of immunotherapy platforms in a number of other oncology indications, including pancreatic cancer, mesothelioma and glioblastoma among others."
自從我們?cè)诮衲晡逶屡c詹森公司就新的前列腺癌免疫療法簽訂首個(gè)協(xié)議以來(lái)，他們是極好的合作伙伴，我們已經(jīng)建立了強(qiáng)有力的合作，專注于在他們的許可適應(yīng)癥里推廣我們的技術(shù)。Aduro公司的董事長(zhǎng)、總裁和首席執(zhí)行官Stephen T. Isaacs說(shuō)。“我相信我們的LADD技術(shù)對(duì)于治療肺癌提供了巨大的希望，并且我們很樂(lè)意與詹森公司擴(kuò)大合作，該公司專注肺癌和前列腺癌治療，擁有豐富的經(jīng)驗(yàn)和資源。Aduro將繼續(xù)單獨(dú)地在許多其他癌癥適應(yīng)癥中發(fā)展我們廣泛的免疫療法平臺(tái)，包括胰腺癌、間皮瘤和其他惡性膠質(zhì)瘤。
The transaction is subject to clearance by the US antitrust authorities under the Hart-Scott-Rodino Act and will become final as soon as such clearance has occurred.
該交易還需要美國(guó)反壟斷局根據(jù)《斯科特•羅迪諾反壟斷改進(jìn)法案》做出正式許可，并且一經(jīng)許可，即刻生效。
In May of this year, Aduro announced its first agreement with Janssen Biotech, Inc. granting the company an exclusive, worldwide license to certain product candidates specifically engineered for the treatment of prostate cancer based on its novel LADD immunotherapy platform. Under that agreement, also facilitated by the Johnson & Johnson Innovation center in California, Aduro is eligible to receive up to $365 million in upfront and development and commercialization milestones.
在今年5月，Aduro公司宣布與詹森生物科技公司達(dá)成首個(gè)協(xié)議，授權(quán)該公司基于其創(chuàng)新的LADD免疫治療平臺(tái)，專門(mén)用于治療前列腺癌的集中候選產(chǎn)品的排他性的世界范圍內(nèi)的生產(chǎn)許可。根據(jù)該協(xié)議，并借助位于加利福尼亞州的強(qiáng)生創(chuàng)新中心，Aduro公司能夠獲得提前支付，以及研發(fā)和商業(yè)化階段總額達(dá)到3.65億美元的收入。
評(píng)論
打印
